Acelyrin, a Los Angeles, CA-based late-stage clinical biopharma company, raised $300M in Series C funding.
The round was led by Access Biotechnology with participation from existing investors AyurMaya – an affiliated fund of Matrix Capital Management, Westlake Village BioPartners, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, Samsara BioCapital, Surveyor Capital (a Citadel company), Tybourne Capital Management, and venBio Partners.
The company intends to use the funds to continue development of izokibep in hidradenitis suppurativa (HS) and uveitis, explore several potential new indications, and continue to pursue portfolio expansion through high-value business development opportunities.
Led by Shao-Lee Lin, MD, PhD, co-founder and CEO, Acelyrin is a biopharma company focused on providing patients new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. Under an exclusive licensing arrangement with Affibody AB, Acelyrin holds global development and commercialization rights to izokibep, including in the United States, European Union, and Japan (excluding select Asian countries).
FinSMEs
13/09/2022